ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stage MONT-SAINT-GUIBERT, Belgium, Dec. 11, 2024 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company empowering cells in ...
ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...
This research report provides valuable insights into the current market situation, drawing information and analysis from various sources. It scrutinizes prominent industry players, presenting details ...